Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.

Article Details

Citation

Copy to clipboard

Patel UJ, Caulfield S

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.

J Adv Pract Oncol. 2019 Jul;10(5):501-507. doi: 10.6004/jadpro.2019.10.5.8. Epub 2019 Jul 1.

PubMed ID

33457063 [ View in PubMed

]

Abstract

Prostate cancer is the fourth leading cause of cancer in the United States. Treatment of this oncologic disease involves a variety of different modalities including surgery, radiation, and systemic therapy. Systemic therapy is used for locally advanced and metastatic disease, and primarily involves hormonal blockade as a mechanism of disease control. Apalutamide is a nonsteroidal androgen receptor inhibitor that binds directly to the androgen receptor ligand binding-domain to prevent androgen receptor translocation. This agent is used in combination with gonadotropin-releasing hormone antagonists to shut down the production of testosterone through the reproductive system. It is the first drug to receive U.S. Food & Drug Administration approval for the treatment of nonmetastatic, castration-resistant prostate cancer. This article reviews the pharmacology of apalutamide along with its current place in therapy and management of associated adverse events.

DrugBank Data that Cites this Article

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Apalutamide	Serum albumin	Protein	Humans	No	Binder	Details